Sanofi Stock Price, News & Analysis (EPA:SAN)

€64.55 -0.34 (-0.52 %)
(As of 02/23/2018 06:39 AM ET)
Previous Close€64.89
Today's Range€64.42 - €65.09
52-Week Range€63.09 - €92.97
Volume362,545 shs
Average Volume3.33 million shs
Market Capitalization$81.54 billion
P/E Ratio16.26
Dividend Yield4.59%
BetaN/A

About Sanofi (EPA:SAN)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Receive SAN News and Ratings via Email

Sign-up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorHealthcare
SymbolEPA:SAN
CUSIPN/A
Phone+33-1-53774000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio16.2594458438287
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS€3.97
Net IncomeN/A
Net Margins-0.27%
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares1,260,000,000

Sanofi (EPA:SAN) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the EPA under the ticker symbol "SAN."

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2018?

15 brokers have issued twelve-month target prices for Sanofi's stock. Their predictions range from €65.00 to €95.00. On average, they anticipate Sanofi's share price to reach €83.07 in the next year. View Analyst Ratings for Sanofi.

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board (Age 66)
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director (Age 61)
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee (Age 59)
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee (Age 58)
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee (Age 54)
  • Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee (Age 53)
  • Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee
  • Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee (Age 55)
  • David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee (Age 55)

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately €64.55.

How big of a company is Sanofi?

Sanofi has a market capitalization of $81.54 billion.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.


MarketBeat Community Rating for Sanofi (SAN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  390 (Vote Outperform)
Underperform Votes:  484 (Vote Underperform)
Total Votes:  874
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sanofi (EPA:SAN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.272.292.272.27
Ratings Breakdown: 1 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €83.07€86.79€88.20€88.57

Sanofi (EPA:SAN) Consensus Price Target History

Price Target History for Sanofi (EPA:SAN)

Sanofi (EPA:SAN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/20/2018BarclaysSet Price TargetSell€65.00View Rating Details
2/19/2018Kepler Capital MarketsSet Price TargetBuy€81.00View Rating Details
2/14/2018Berenberg BankSet Price TargetNeutral€81.00View Rating Details
2/12/2018CfraSet Price TargetNeutral€70.00View Rating Details
2/8/2018Societe GeneraleSet Price TargetBuy€94.00View Rating Details
2/8/2018Deutsche BankSet Price TargetBuy€93.00View Rating Details
2/8/2018Credit Suisse GroupSet Price TargetBuy€95.00View Rating Details
2/7/2018Sanford C. BernsteinSet Price TargetNeutral€82.00View Rating Details
2/7/2018Goldman Sachs GroupSet Price TargetNeutral€82.00View Rating Details
1/23/2018S&P GlobalSet Price TargetNeutral€78.00View Rating Details
1/16/2018Jefferies GroupSet Price TargetNeutral€80.00View Rating Details
11/2/2017JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
10/26/2017Morgan StanleySet Price TargetBuy€92.00View Rating Details
10/6/2017CitigroupSet Price TargetNeutral€88.00View Rating Details
9/12/2017BNP ParibasSet Price TargetNeutral€85.00View Rating Details
12/6/2016S&P GlobalSet Price TargetNeutral€80.00View Rating Details
6/30/2016Independent ResearchSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
(Data available from 2/23/2016 forward)

Earnings

Earnings History for Sanofi (EPA:SAN)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Sanofi (EPA:SAN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sanofi (EPA:SAN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sanofi (EPA SAN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Sanofi (EPA SAN) News Headlines

Source:
DateHeadline
Global cancer vaccines market expected to be driven by increasing incidence of cancerGlobal cancer vaccines market expected to be driven by increasing incidence of cancer
www.marketwatch.com - February 22 at 8:37 AM
Sanofi (SAN) Given a €65.00 Price Target by Barclays AnalystsSanofi (SAN) Given a €65.00 Price Target by Barclays Analysts
www.americanbankingnews.com - February 20 at 4:00 PM
Sanofi SA (SAN) Given Consensus Recommendation of "Hold" by AnalystsSanofi SA (SAN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 20 at 7:30 AM
Sanofi: Disclosure of trading in own sharesSanofi: Disclosure of trading in own shares
finance.yahoo.com - February 19 at 4:59 PM
Sanofi (SAN) Given a €81.00 Price Target by Kepler Capital Markets AnalystsSanofi (SAN) Given a €81.00 Price Target by Kepler Capital Markets Analysts
www.americanbankingnews.com - February 19 at 10:48 AM
Sanofi (SAN) PT Set at €81.00 by Berenberg BankSanofi (SAN) PT Set at €81.00 by Berenberg Bank
www.americanbankingnews.com - February 18 at 12:42 PM
Nestle CEO Schneider Seeks Deals as Sales Growth StuttersNestle CEO Schneider Seeks Deals as Sales Growth Stutters
www.msn.com - February 15 at 8:05 AM
Sanofi : Information concerning the total number of voting rights and sharesSanofi : Information concerning the total number of voting rights and shares
finance.yahoo.com - February 13 at 9:49 AM
Sanofi (SAN) Given a €70.00 Price Target by Cfra AnalystsSanofi (SAN) Given a €70.00 Price Target by Cfra Analysts
www.americanbankingnews.com - February 12 at 6:12 AM
Credit Suisse Group Analysts Give Sanofi (SAN) a €95.00 Price TargetCredit Suisse Group Analysts Give Sanofi (SAN) a €95.00 Price Target
www.americanbankingnews.com - February 11 at 5:55 PM
Deutsche Bank Reiterates "€93.00" Price Target for Sanofi (SAN)Deutsche Bank Reiterates "€93.00" Price Target for Sanofi (SAN)
www.americanbankingnews.com - February 11 at 4:00 PM
Sanofi (SAN) Given a €94.00 Price Target by Societe Generale AnalystsSanofi (SAN) Given a €94.00 Price Target by Societe Generale Analysts
www.americanbankingnews.com - February 11 at 11:58 AM
Sanofi net profit slide on sales drop, chargeSanofi net profit slide on sales drop, charge
www.marketwatch.com - February 8 at 3:53 PM
Sanofi misses Street 4Q forecastsSanofi misses Street 4Q forecasts
finance.yahoo.com - February 7 at 9:50 AM
Sanofi Delivers 2017 Business EPS in line with GuidanceSanofi Delivers 2017 Business EPS in line with Guidance
finance.yahoo.com - February 7 at 9:50 AM
Sanofis return to profit growth this year slower than hopedSanofi's return to profit growth this year slower than hoped
finance.yahoo.com - February 7 at 9:50 AM
Sanofi (SAN) Given a €83.00 Price Target at Kepler Capital MarketsSanofi (SAN) Given a €83.00 Price Target at Kepler Capital Markets
www.americanbankingnews.com - February 6 at 6:20 AM
Glaxo, Reckitt Are Said to Be Only Suitors for Pfizers Division - BloombergGlaxo, Reckitt Are Said to Be Only Suitors for Pfizer's Division - Bloomberg
www.bloomberg.com - February 5 at 9:41 AM
Initial Philippines Probe Finds ‘Causal Association’ Between Deaths, Sanofi Dengue VaccineInitial Philippines Probe Finds ‘Causal Association’ Between Deaths, Sanofi Dengue Vaccine
www.wsj.com - February 2 at 9:45 AM
Onduo, backed by $500M from Alphabet and Sanofi, launches ‘virtual diabetes clinic’Onduo, backed by $500M from Alphabet and Sanofi, launches ‘virtual diabetes clinic’
www.bizjournals.com - February 2 at 9:45 AM
[$$] Initial Philippines Probe Finds Causal Association Between Deaths, Dengue Vaccine[$$] Initial Philippines Probe Finds 'Causal Association' Between Deaths, Dengue Vaccine
finance.yahoo.com - February 2 at 9:45 AM
Philippines: 3 deaths may be linked to dengue vaccinationsPhilippines: 3 deaths may be linked to dengue vaccinations
finance.yahoo.com - February 2 at 9:45 AM
Sanofi: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatmentSanofi: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment
finance.yahoo.com - January 31 at 10:08 AM
UBS Group Analysts Give Sanofi (SAN) a €82.00 Price TargetUBS Group Analysts Give Sanofi (SAN) a €82.00 Price Target
www.americanbankingnews.com - January 30 at 6:14 AM
Sanofi to Pay $4.85 Billion for Biotech Focused on Small AntibodiesSanofi to Pay $4.85 Billion for Biotech Focused on Small Antibodies
www.wsj.com - January 29 at 9:56 AM
Sanofi (SAN) Given a €82.00 Price Target by Goldman Sachs Group AnalystsSanofi (SAN) Given a €82.00 Price Target by Goldman Sachs Group Analysts
www.americanbankingnews.com - January 29 at 6:22 AM
SEC Alleges Insider Trading Ahead of Sanofi’s Purchase of BioverativSEC Alleges Insider Trading Ahead of Sanofi’s Purchase of Bioverativ
www.wsj.com - January 27 at 10:05 AM
Sanofi sees forex effects negatively hitting salesSanofi sees forex effects negatively hitting sales
www.marketwatch.com - January 24 at 8:20 AM
Sanofi: Availability of the Pre-quarterly Results CommunicationSanofi: Availability of the Pre-quarterly Results Communication
finance.yahoo.com - January 23 at 5:14 PM
Sanofi And Celgene Are The Latest To Acquire Promising BiotechsSanofi And Celgene Are The Latest To Acquire Promising Biotechs
finance.yahoo.com - January 23 at 5:14 PM
S&P Global Analysts Give Sanofi (SAN) a €78.00 Price TargetS&P Global Analysts Give Sanofi (SAN) a €78.00 Price Target
www.americanbankingnews.com - January 23 at 6:46 AM
Sanofi (SAN) Given a €97.00 Price Target at Berenberg BankSanofi (SAN) Given a €97.00 Price Target at Berenberg Bank
www.americanbankingnews.com - January 22 at 10:36 AM
Deutsche Bank Analysts Give Sanofi (SAN) a €93.00 Price TargetDeutsche Bank Analysts Give Sanofi (SAN) a €93.00 Price Target
www.americanbankingnews.com - January 20 at 11:44 PM
Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive CommitteeSanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee
finance.yahoo.com - January 19 at 3:16 PM
Big Pharma, Big DividendsBig Pharma, Big Dividends
www.forbes.com - January 18 at 3:17 PM
Alnylam stock more than tripled last year — and the company says 2018 will be bigAlnylam stock more than tripled last year — and the company says 2018 will be big
finance.yahoo.com - January 17 at 3:16 PM
Sanofi (SAN) PT Set at €80.00 by Jefferies GroupSanofi (SAN) PT Set at €80.00 by Jefferies Group
www.americanbankingnews.com - January 16 at 9:34 AM
Flu season ramped up in last weeks of 2017Flu season ramped up in last weeks of 2017
finance.yahoo.com - January 12 at 5:25 AM
Regeneron, Sanofi Expand Investment in Cemiplimab & DupilumabRegeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab
finance.yahoo.com - January 9 at 3:15 PM
Alnylam, Sanofi to restructure rare-disease effort - MarketWatchAlnylam, Sanofi to restructure rare-disease effort - MarketWatch
www.marketwatch.com - January 9 at 5:36 AM
Biotech CEO Turned Failed Sanofi Drug Into Multibillion Deal - BloombergBiotech CEO Turned Failed Sanofi Drug Into Multibillion Deal - Bloomberg
www.bloomberg.com - January 9 at 5:36 AM
Biotech CEO Turned Failed Sanofi Drug Into Multibillion DealBiotech CEO Turned Failed Sanofi Drug Into Multibillion Deal
finance.yahoo.com - January 9 at 5:36 AM
Sanofi : Disclosure of trading in own sharesSanofi : Disclosure of trading in own shares
finance.yahoo.com - January 8 at 3:16 PM
APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi - GlobeNewswire (press release)APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi - GlobeNewswire (press release)
globenewswire.com - January 8 at 11:19 AM
Sanofi to market new hemophilia drug in deal with Alnylam - ReutersSanofi to market new hemophilia drug in deal with Alnylam - Reuters
www.reuters.com - January 8 at 11:19 AM
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs - GlobeNewswire (press release)Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs - GlobeNewswire (press release)
globenewswire.com - January 8 at 11:19 AM
Targovax announces the appointment of Michael Bogenstaetter as Chief Business OfficerTargovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
feeds.benzinga.com - January 8 at 2:59 AM
Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance - Business Wire (press release)Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance - Business Wire (press release)
www.businesswire.com - January 7 at 3:15 PM
Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease allianceSanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
finance.yahoo.com - January 7 at 3:15 PM
Brainstorm Health: RNA Interference, Sanofi Dengue Vaccine ... - FortuneBrainstorm Health: RNA Interference, Sanofi Dengue Vaccine ... - Fortune
fortune.com - January 5 at 5:25 AM

SEC Filings

Sanofi (EPA:SAN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Sanofi (EPA SAN) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.